SAN FRANCISCO and VANCOUVER, British Columbia — October 7, 2025 — Leads & Copy — Jade Biosciences, Inc. (Nasdaq: JBIO) has unveiled JADE201, an investigational monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R), designed to treat autoimmune diseases. The company says JADE201 combines a dual mechanism of action and half-life extension technology to improve the clinical benefit of existing B-cell depleting therapies.
According to Jade CEO Tom Frohlich, JADE201 complements their portfolio of B-cell biology therapies, including JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy. Andrew King, Chief Scientific Officer, added that JADE201 builds on the clinical validation of targeting BAFF-R, combining enhanced B cell depletion with blockade of BAFF-R mediated survival and activation signals. Jade expects to begin a trial in rheumatoid arthritis in the first half of 2026.
JADE201 incorporates afucosylation to enhance antibody-dependent cellular toxicity and a clinically validated Fc mutation to increase neonatal Fc receptor binding, extending systemic exposure while preserving activity.
The company will host a conference call and webcast today, October 7, 2025, at 8:00 a.m. ET, to discuss the JADE201 profile. Investors can register on the company’s website.
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
Source: Jade Biosciences, Inc.
